SPL Medical – Innovative Research
and development in cancer diagnostics.

The goal of SPL Medical is to develop and research new technologies that sustainably improve imaging procedures in diagnostics, so that lymph node metastases and inflammatory activities in the body can be detected more precisely and significantly earlier, patient lives can be extended and the quality of life of those affected can be noticeably increased. SPL Medical is a spin-off from Radboud University Nijmegen and is supported by Oost NL and b.e.imaging, a German specialist in contrast media.

The revolution
in early detection of metastases.

The revolution
in early detection of metastases.

DETECTING
METASTASES
TODAY.
Conventional MRI or CT only show lymph node metastases of about 8 mm in size.
DETECTING
METASTASES WITH
FERUMOXTRAN.See smaller.
The new active ingredient enables for the first time to detect metastases with a diameter of just 2 mm.
DETECTING
METASTASES
IN NANOPARTICLE MRI.SEE MORE.
Significantly more affected areas can be seen on the clear and high-contrast MRI image.
More targeted
prognosis
for therapy.SEE SOONER.
Significant time savings through earlier and more precise treatment.
Animation überspringen

Successful international studies
already in phase III.

In order to register the globally novel agent in Europe and Germany, a registration trial with Ferrotran® is currently underway at several well-known European clinics for the detection of pelvic lymph node metastases in prostate cancer patients. To date, more than 700 prostate cancer patients have been diagnosed with Ferrotran® , giving them earlier and more specific treatment and a significantly higher chance of recovery.

Successful international studies already in phase III.

In order to register the globally novel agent in Europe and Germany, a registration trial with Ferrotran® is currently underway at several well-known European clinics for the detection of pelvic lymph node metastases in prostate cancer patients. To date, more than 700 prostate cancer patients have been diagnosed with Ferrotran® , giving them earlier and more specific treatment and a significantly higher chance of recovery.

Publications
and news

SPL Medical has entered into an Agreement with Sanochemia Pharmazeutika GmbH for supply and worldwide distribution of Ferrotran® (Ferumoxtran) for detection of Lymph node metastases by Magnetic Resonance Imaging (MRI).

The business agreement, signed by SPL Medical and Sanochemia Pharmazeutika, is a comprehensive contract. The agreement grants Sanochemia worldwide exclusivity regarding the supply and distribution of Ferrotran® (an iron oxide-based nanoparticle) for use in Magnetic Resonance Imaging (MRI) except for Germany, Austria and Switzerland. These

Learn more >>

bender gruppe startet ein KI-Projekt

Die bender gruppe gibt bekannt, dass sie mit der Entwicklung einer KI-Software zur Detektion von Mikrometastasen mittels MRT-Scans von Lymphknoten bei Prostatakrebserkrankungen begonnen hat. Die bender gruppe ist 100%-ige Gesellschafterin der medigration GmbH aus Erlangen, einem etablierten RIS/PACS-Entwicklungsunternehmen sowie Mehrheitsgesellschafterin der SPL Medical BV, mit

Learn more >>
That's all for now...

Abonnieren Sie unseren Newsletter und bleiben Sie in Sachen SPL-Medical und Ferrotran® auf dem Laufendem.